237 related articles for article (PubMed ID: 7930556)
1. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension.
Douglas SA; Gellai M; Ezekiel M; Ohlstein EH
J Hypertens; 1994 May; 12(5):561-7. PubMed ID: 7930556
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670.
Douglas SA; Gellai M; Ezekiel M; Feuerstein GZ; Elliott JD; Ohlstein EH
Hypertension; 1995 Apr; 25(4 Pt 2):818-22. PubMed ID: 7721437
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats.
Ohlstein EH; Douglas SA; Ezekiel M; Gellai M
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S321-4. PubMed ID: 7509976
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
Schiffrin EL; Turgeon A; Deng LY
Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
[TBL] [Abstract][Full Text] [Related]
5. Impaired response of the denervated kidney to endothelin receptor blockade in normotensive and spontaneously hypertensive rats.
Girchev R; Bäcker A; Markova P; Kramer HJ
Kidney Int; 2004 Mar; 65(3):982-9. PubMed ID: 14871418
[TBL] [Abstract][Full Text] [Related]
6. Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP.
Nakamura K; Sasaki S; Moriguchi J; Morimoto S; Miki S; Kawa T; Itoh H; Nakata T; Takeda K; Nakagawa M
J Cardiovasc Pharmacol; 1999 Jun; 33(6):876-82. PubMed ID: 10367590
[TBL] [Abstract][Full Text] [Related]
7. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.
McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS
Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029
[TBL] [Abstract][Full Text] [Related]
8. Differential haemodynamic effects of endothelin receptor antagonist, SB 209670, in conscious hypertensive and normotensive rats.
Bunting MW; Widdop RE
Eur J Pharmacol; 1999 Sep; 381(1):13-21. PubMed ID: 10528129
[TBL] [Abstract][Full Text] [Related]
9. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats.
Hocher B; Rohmeiss P; Zart R; Diekmann F; Vogt V; Metz D; Fakhury M; Gretz N; Bauer C; Koppenhagen K; Neumayer HH; Distler A
Cardiovasc Res; 1996 Apr; 31(4):499-510. PubMed ID: 8689641
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effects of BQ-123, a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt.
Okada M; Fukuroda T; Shimamoto K; Takahashi R; Ikemoto F; Yano M; Nishikibe M
Eur J Pharmacol; 1994 Jul; 259(3):339-42. PubMed ID: 7982465
[TBL] [Abstract][Full Text] [Related]
11. Effects of nitric oxide synthase inhibition and endothelin ETA receptor blockade on haemodynamics in hypertensive rats.
Granstam SO; Lind L; Granstam E; Fellström B
Clin Exp Pharmacol Physiol; 1998 Sep; 25(9):693-701. PubMed ID: 9750958
[TBL] [Abstract][Full Text] [Related]
12. Interaction between endothelin and nitric oxide in sympathetic nerve modulation in hypertensive rats.
Kumagai H; Suzuki H; Ichikawa M; Nishizawa M; Oshima N; Saruta T
Hypertens Res; 1997 Mar; 20(1):35-42. PubMed ID: 9101311
[TBL] [Abstract][Full Text] [Related]
13. Significance of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats: renal and hemodynamic effects of endothelin receptor antagonists.
Hocher B; Rohmeiss P; Zart R; Diekmann F; Vogt V; Metz D; Fakhury M; Gretz N; Bauer C; Koppenhagen K
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S470-2. PubMed ID: 8587449
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure variability in conscious spontaneously hypertensive rats during endothelin A receptor inhibition.
Girchev R; Markova P
Methods Find Exp Clin Pharmacol; 2004; 26(1):25-9. PubMed ID: 14988738
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model.
Nishikibe M; Tsuchida S; Okada M; Fukuroda T; Shimamoto K; Yano M; Ishikawa K; Ikemoto F
Life Sci; 1993; 52(8):717-24. PubMed ID: 8446001
[TBL] [Abstract][Full Text] [Related]
16. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
17. Enhanced slow-pressor response to angiotensin II in spontaneously hypertensive rats.
Li P; Jackson EK
J Pharmacol Exp Ther; 1989 Dec; 251(3):909-21. PubMed ID: 2557422
[TBL] [Abstract][Full Text] [Related]
18. Impaired potentiation by endothelin-1 and vasopressin of sympathetic contraction in tail artery from hypertensive rats.
García-Villalón AL; Monge L; Fernández N; Sánchez MA; Martínez MA; Gómez B; Diéguez G
Cardiovasc Res; 2000 Jan; 45(2):463-9. PubMed ID: 10728367
[TBL] [Abstract][Full Text] [Related]
19. Endothelin contributes to the hemodynamic effects of vasopressin in spontaneous hypertension.
Balakrishnan SM; Gopalakrishnan V; McNeill JR
Eur J Pharmacol; 1997 Sep; 334(1):55-60. PubMed ID: 9346328
[TBL] [Abstract][Full Text] [Related]
20. Effects of endothelin receptor type A antagonism and nitric oxide synthase inhibition on cerebral blood flow in hypertensive rats.
Granstam SO; Granstam E; Fellström B; Lind L
Acta Physiol Scand; 1998 Oct; 164(2):213-8. PubMed ID: 9805108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
